112 related articles for article (PubMed ID: 20720388)
1. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Degen A; Satzger I; Voelker B; Kapp A; Hauschild A; Gutzmer R
Dermatology; 2010; 221(3):193-6. PubMed ID: 20720388
[TBL] [Abstract][Full Text] [Related]
2. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Smith KJ; Haley H; Hamza S; Skelton HG
Dermatol Surg; 2009 Nov; 35(11):1766-70. PubMed ID: 19660024
[TBL] [Abstract][Full Text] [Related]
3. The histologic spectrum of epithelial neoplasms induced by sorafenib.
Kwon EJ; Kish LS; Jaworsky C
J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Diamantis ML; Chon SY
J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
[TBL] [Abstract][Full Text] [Related]
5. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Lynch MC; Straub R; Adams DR
J Drugs Dermatol; 2011 Mar; 10(3):308-10. PubMed ID: 21369650
[TBL] [Abstract][Full Text] [Related]
6. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
[TBL] [Abstract][Full Text] [Related]
7. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
9. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Hong DS; Reddy SB; Prieto VG; Wright JJ; Tannir NM; Cohen PR; Diwan AH; Evans HL; Kurzrock R
Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
[TBL] [Abstract][Full Text] [Related]
10. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP; Mateus C; Escudier B; Tomasic G; Wechsler J; Hollville E; Soria JC; Malka D; Sarasin A; Larcher M; André J; Kamsu-Kom N; Boussemart L; Lacroix L; Spatz A; Eggermont AM; Druillennec S; Vagner S; Eychène A; Dumaz N; Robert C
Clin Cancer Res; 2012 Jan; 18(1):263-72. PubMed ID: 22096025
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib-induced premalignant and malignant skin lesions.
Williams VL; Cohen PR; Stewart DJ
Int J Dermatol; 2011 Apr; 50(4):396-402. PubMed ID: 21413947
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
14. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
16. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Arnault JP; Wechsler J; Escudier B; Spatz A; Tomasic G; Sibaud V; Aractingi S; Grange JD; Poirier-Colame V; Malka D; Soria JC; Mateus C; Robert C
J Clin Oncol; 2009 Aug; 27(23):e59-61. PubMed ID: 19597016
[No Abstract] [Full Text] [Related]
17. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
18. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
19. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
20. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]